

 
Adverse effects are mainly related to its [[antimuscarinic]] effects. Common [[adverse drug reaction]]s (≥1% of patients) associated with tiotropium therapy include: dry mouth and/or throat irritation. Rarely (<0.1% of patients) treatment is associated with:[[urinary retention]], constipation, acute [[angle closure glaucoma]], palpitations (notably [[supraventricular tachycardia]] and [[atrial fibrillation]]) and/or allergy (rash, [[angioedema]], [[anaphylaxis]]).<ref>{{cite book |editor=Rossi S |title=[[Australian Medicines Handbook]] |location=Adelaide |year=2006 }}</ref>

 


 
Tiotropium and another member of its class [[ipratropium]] were linked to increased risk of heart attacks, stroke and cardiovascular death.<ref>{{cite journal |vauthors=Singh S, Loke YK, Furberg CD |title=Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis |journal=JAMA |volume=300 |issue=12 |pages=1439–50 |date=September 2008 |pmid=18812535 |doi=10.1001/jama.300.12.1439 |url=http://jama.ama-assn.org/cgi/pmidlookup?view=long&pmid=18812535}}</ref> The FDA requested further trials; these are now complete, and adequately resolve the previous safety concerns.<ref>[http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm197429.htm FDA. Follow-Up to the October 2008 Updated Early Communication about an Ongoing Safety Review of Tiotropium (marketed as Spiriva HandiHaler). FDA 2010]</ref>

 


 
Tiotropium mist inhaler ([[Respimat]]) has been found to be associated with an increase of all cause mortality in people with COPD.<ref>{{cite journal|last=Singh|first=S |author2=Loke, YK |author3=Enright, PL |author4=Furberg, CD|title=Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials.|journal=BMJ (Clinical research ed.)|date=Jun 14, 2011|volume=342|pages=d3215|pmid=21672999|doi=10.1136/bmj.d3215|pmc=3114950}}</ref>

 

